drugset / Trial / NCT01582477

TAP-patients With Robotic Assisted Lap Prostatectomy

NCT01582477 ↗

Phase 4 Completed 24 enrolled Pacira Pharmaceuticals, Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.